三生制药气从何来?是固步自封还是冲击百亿市场的王者?

南方都市报
22 Oct 2024

今年以来,资本市场特别是香港市场的打压,再加上美联储降息消息的反反复复,让国内不少生物医药上市企业都憋着一口气。回购,已成了自救的一种集体行动。回购公告中“委屈”的共识是:看好公司发展前景,目前股价低于公司实际价值。和药明生物、石药集团等公司的回购计划比起来,同在港交所上市的三生制药(01530.HK)的气或许憋得更甚,因为它出手更早,下手也更重。三生制药回购列表部分明细截图。仅2024年上半年,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10